Therapeutic Area | MeSH |
---|---|
cardiovascular diseases | D002318 |
Brand Name | Status | Last Update |
---|---|---|
bystolic | New Drug Application | 2024-08-23 |
nebivolol | ANDA | 2025-03-17 |
nebivolol hydrochloride | ANDA | 2023-07-11 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | — | 1 |
Left ventricular hypertrophy | D017379 | EFO_0003896 | — | — | — | — | 1 | — | 1 |
Blood pressure | D001794 | EFO_0004325 | — | — | — | — | 1 | — | 1 |
Hypertrophy | D006984 | EFO_0002460 | — | — | — | — | 1 | — | 1 |
Drug common name | Nebivolol |
INN | nebivolol |
Description | 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] is a member of the class of chromanes that is 2,2'-iminodiethanol in which one hydrogen attached to each hydroxy-bearing carbon is replaced by a 6-fluorochroman-2-yl group. It is an organofluorine compound, a secondary amino compound, a secondary alcohol, a diol and a member of chromanes. |
Classification | Small molecule |
Drug class | beta-blockers (propranolol type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1 |
PDB | — |
CAS-ID | 99200-09-6 |
RxCUI | — |
ChEMBL ID | CHEMBL434394 |
ChEBI ID | 64019 |
PubChem CID | 71301 |
DrugBank | DB04861 |
UNII ID | 030Y90569U (ChemIDplus, GSRS) |